Objective: To discuss the effect of modified Geqi powder combined concurrent chemoradiotherapy on quality of life and immunoregulation in treating patients with middle and terminal esophageal cancer. Method: One hundred and fifteen patients with middle and terminal esophageal cancer were randomly divided into the control group (57 cases) and the observation group (58 cases) by a random number table. Patients in the control group received three dimensional conformal radiation therapy and synchronous chemotherapy. Based on the treatment of the control group

patients in the observation group added modified Geqi powder. All patients in two groups received 12 weeks of treatment. The detectable lesion was detected by CT or MRI. Before and after treatment

symptoms and signs were recorded. Patients' life of quality was evaluated by esophageal cancer specific scale (QLQ-OES18). Levels of CD3+

CD4+ and CD4+/CD8+ of T cell subpopulations and natural killer cell (NK) were detected. Safety was monitored during the treatment. Result: The efficient of solid tumor in the observation group was 70.69%

which was higher than that of 56.14% in the control group

while there was no statistically significant difference between two groups. After treatment

scores of dysphagia

difficulty in feeding

pain

drool

swallowing obstruction

dry mouth and appetite were lower

levels of CD3+

CD4+ and NK were higher in the observation group than those in the control group (P<0.01). The occurrence degree of acute radiation injury (P<0.05) and nausea and vomit (P<0.01) were lower than those in the control group (P<0.01). Conclusion: Modified Geqi powder could ameliorate clinical symptoms and signs

relieve toxic and side effect of radiotherapy and chemotherapy

and improve bodies' immune function and quality of life

and it has an obvious short-term effect.